Summary

It is the industry analysis specialist’s new report, “Pulmonary Arterial Hypertension (PAH) - Drug Pipeline Analysis and Market Forecasts to 2016"" is an essential source of information and analysis on the global PAH market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global PAH market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global PAH sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by its team of industry experts.

Scope

The scope of the report includes:
- Annualized global PAH market revenues data from 2005 to 2009, forecast forward for seven years to 2016.
- Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data provides a split across different phases, mechanism of actions being developed and emerging trends. Key classes of mechanism of action include endothelin receptor antagonists, platelet aggregation inhibitors, phosphodiesterase inhibitors, serotonin pathway antagonists, angiotensin receptor antagonists, P2Y 12 receptor inhibitors, PDE5 inhibitors, prostacyclin (PGI2) agonists, nitric oxide synthetase inhibitors.
- Analysis of the current and future market competition in the global PAH market. Key market players covered are Actelion Ltd.,United Therapeutics Corporation, Bayer AG, Gilead Sciences, Pfizer Inc., Novartis AG, Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly and Company, Lung RX and GlaxoSmithKline Plc.
- Insightful reviews of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with PAH.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global PAH market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global PAH market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global PAH market landscape? – Identify, understand and capitalize.

Company Mentioned
Actelion Ltd.
United Therapeutics Corporation
Bayer AG
Gilead Sciences
Pfizer AG
Novartis AG
Bristol-Myers Squibb
Sanofi-Aventis
Eli Lilly and Company
Lung RX
GlaxoSmithKline.

1
1 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Pulmonary Arterial Hypertension Market: Market Characterization 6
2.1 Overview 6
2.2 Pulmonary Arterial Hypertension Market Size 6
2.3 Pulmonary Arterial Hypertension Market Forecast and CAGR 7
2.4 Drivers and Barriers for the Pulmonary Arterial Hypertension Market 8
2.4.1 Drivers for the Pulmonary Arterial Hypertension Market 8
2.4.2 Barriers for the Pulmonary Arterial Hypertension Market 8
2.5 Opportunity and Unmet Need 9
2.6 Key Takeaway 10
3 Pulmonary Arterial Hypertension Market: Competitive Assessment 11
3.1 Overview 11
3.2 Strategic Competitor Assessment 11
3.3 Product Profile for the Major Marketed Products in the Pulmonary Arterial Hypertension Market 12
3.3.1 Tracleer 12
3.3.2 Remodulin 13
3.3.3 Revatio 14
3.3.4 Ventavis 15
3.3.5 Letairis 16
3.3.6 Adcirca 18
3.4 Key Takeaway 22
4 Pulmonary Arterial Hypertension Market: Pipeline Assessment 23
4.1 Overview 23
4.2 Strategic Pipeline Assessment 23
4.2.1 Technology Trends Analytical Framework 23
4.3 Pulmonary Arterial Hypertension Therapeutics – Promising Drugs under Clinical Development 25
4.4 Molecule Profile for Promising Drugs under Clinical Development 26
4.4.1 Iloprost 26
4.4.2 ACT-064992 26
4.4.3 Viveta 27
4.4.4 ACT-293987 27
4.4.5 Riociguat (BAY63-2521) 28
4.5 Pulmonary Arterial Hypertension Pipeline – Pipeline by Clinical Phases of Development 29
4.5.1 Pulmonary Arterial Hypertension Therapeutics – NDA Filed 30
4.5.2 Pulmonary Arterial Hypertension Therapeutics – Phase III Clinical Pipeline 31
4.5.3 Pulmonary Arterial Hypertension Therapeutics – Phase II Clinical Pipeline 32
4.5.4 Pulmonary Arterial Hypertension Therapeutics – Phase I Clinical Pipeline 33
4.5.5 Pulmonary Arterial Hypertension Therapeutics – Preclinical Pipeline 33
4.6 Discontinued/ Suspended Drugs for Pulmonary Arterial Hypertension 34
4.6.1 Key Takeaway 34
5 Global Pulmonary Arterial Hypertension Market: Implications for Future Market Competition 35
6 Pulmonary Arterial Hypertension Market: Future Players in the Pulmonary Arterial Hypertension Market 37
6.1 Introduction 37
6.2 Actelion Ltd. 38
6.2.1 Company Overview 38
6.2.2 Business Description 38
6.2.3 Company Pipeline 39
6.3 United Therapeutics Corporation 39
6.3.1 Company Overview 39
6.3.2 Business Description 40
6.3.3 Company Pipeline 40
6.4 Bayer AG 41
6.4.1 Company Overview 41
6.4.2 Business Description 41
6.4.3 Company Pipeline 42
6.5 Gilead Sciences 42
6.5.1 Company Overview 42
6.5.2 Business Description 42
6.5.3 Company Pipeline 43
6.6 Pfizer AG 43
6.6.1 Company Overview 43
6.6.2 Business Description 44
6.6.3 Company Pipeline 44
6.7 Novartis AG 44
6.7.1 Company Overview 44
6.7.2 Business Description 45
6.7.3 Company Pipeline 46
6.8 Bristol-Myers Squibb 46
6.8.1 Company Overview 46
6.8.2 Business Description 46
6.8.3 Company Pipeline 47
6.9 Sanofi-Aventis 47
6.9.1 Company Overview 47
6.9.2 Business Description 47
6.9.3 Company Pipeline 48
6.10 Eli Lilly and Company 48
6.10.1 Company Overview 48
6.10.2 Business Description 48
6.10.3 Company Pipeline 49
6.11 Lung RX 49
6.11.1 Company Overview 49
6.11.2 Business Description 49
6.11.3 Company Pipeline 49
6.12 GlaxoSmithKline 49
6.12.1 Company Overview 49
6.12.2 Business Description 50
6.12.3 Company Pipeline 50
7 Pulmonary Arterial Hypertension Market: Appendix 51
7.1 Definitions 51
7.2 Abbreviations 51
7.3 Research Methodology 52
7.3.1 Coverage 53
7.3.2 Secondary Research 53
7.3.3 Forecasting 54
7.3.4 Primary Research 57
7.3.5 Expert Panels 57
7.4 Contact Us 57
7.5 Disclaimer 57
7.6 Sources 58

1.1 List of Tables
Table 1: Pulmonary Arterial Hypertension Market, Global, Revenues ($m), 2005–2009 7
Table 2: Pulmonary Arterial Hypertension Market, Global, Revenues ($m), 2009–2016 7
Table 3: Major Marketed Products Comparison in Pulmonary Arterial Hypertension Market, 2010 20
Table 4: Pulmonary Arterial Hypertension Therapeutics – Most Promising Drugs Under Clinical Development, 2010 25
Table 5: Pulmonary Arterial Hypertension Therapeutics – NDA Filed, 2010 30
Table 6: Pulmonary Arterial Hypertension Therapeutics – Phase III Clinical Pipeline, 2010 31
Table 7: Pulmonary Arterial Hypertension Therapeutics – Phase II Clinical Pipeline, 2010 32
Table 8: Pulmonary Arterial Hypertension Therapeutics – Phase I Clinical Pipeline, 2010 33
Table 9: Pulmonary Arterial Hypertension Therapeutics – Preclinical Pipeline, 2010 33
Table 10: List of Discontinued/Suspended Drugs for Pulmonary Arterial Hypertension, 2010 34
Table 11: Actelion Ltd. – Pulmonary Arterial Hypertension Pipeline, 2010 39
Table 12: United Therapeutics Ltd. – Pulmonary Arterial Hypertension Pipeline, 2010 40
Table 13: Bayer AG – Pulmonary Arterial Hypertension Pipeline, 2010 42
Table 14: Gilead Sciences – Pulmonary Arterial Hypertension Pipeline, 2010 43
Table 15: Pfizer AG – Pulmonary Arterial Hypertension Pipeline, 2010 44
Table 16: Novartis AG – Pulmonary Arterial Hypertension Pipeline, 2010 46
Table 17: Bristol-Myers Squibb – Pulmonary Arterial Hypertension Pipeline, 2010 47
Table 18: Sanofi-Aventis – Pulmonary Arterial Hypertension Pipeline, 2010 48
Table 19: Eli Lilly & Company – Pulmonary Arterial Hypertension Pipeline, 2010 49
Table 20: Lung RX – Pulmonary Arterial Hypertension Pipeline, 2010 49
Table 21: GlaxoSmithKline plc. – Pulmonary Arterial Hypertension Pipeline, 2010 50"

1.2 List of Figures
Figure 1: Global Pulmonary Arterial Hypertension Market Revenues and Forecast, 2005–2016 7
Figure 2: Opportunity and Unmet Need in the Pulmonary Arterial Hypertension Market, 2010 10
Figure 3: Strategic Competitor Assessment of the Major Marketed Products in Pulmonary Arterial Hypertension Therapeutics, 2010 12
Figure 4: Technology Trends Analytic Framework – Pulmonary Arterial Hypertension Market, 2010 23
Figure 5: Technology Trends Analytic Framework of the Pulmonary Arterial Hypertension Pipeline – Description, 2010 24
Figure 6: Pulmonary Arterial Hypertension Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010 29
Figure 7: Pulmonary Arterial Hypertension Pipeline by Phase of Clinical Development, 2010 29
Figure 8: Implications for Future Market Competition in Pulmonary Arterial Hypertension, 2010 36
Figure 9: Pulmonary Arterial Hypertension Therapeutics Market – Clinical Pipeline by Company, 2010 37
Figure 10: Pulmonary Arterial Hypertension, Global, Companies That Have the Highest Number of Molecules in the Pipeline, 2010 38
Figure 11: GlobalData Methodology 53
Figure 12: GlobalData Market Forecasting Model 56